Dupilumab (Dupixent, Sanofi) is indicated 'in adults as add-on maintenance treatment for uncontrolled chronic obstructive pulmonary disease (COPD) characterised by raised blood eosinophils on a combination of an inhaled corticosteroid (ICS), a long-acting beta2-agonist (LABA), and a long-acting muscarinic antagonist (LAMA), or on a combination of a LABA and a LAMA if ICS is not appropriate'.
The dosage schedule is available in the summary of product characteristics for dupilumab.
The list price of dupilumab is £1,264.89 for a 2‑pack of 300 mg per 2 ml pre-filled pens or pre-filled syringes (excluding VAT; BNF online, accessed December 2025).
The company has a commercial arrangement. This makes dupilumab available to the NHS with a discount. The size of the discount is commercial in confidence.
For information, Sanofi did not disclose its Carbon Reduction Plan for UK carbon emissions.